Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

Rhea-AI Summary

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its third quarter 2021 financial results after U.S. markets close on November 4, 2021. A management webcast will occur at 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide a business update. The company focuses on developing novel oncology therapies, including cirmtuzumab, targeting ROR1, and TK216 for Ewing sarcoma. Oncternal's innovative clinical pipeline addresses significant unmet needs in cancer treatment.

Positive

• The company is advancing its clinical pipeline, including cirmtuzumab in Phase 1/2 trials, indicating progress in oncology treatments.
• Focus on innovative therapies for cancer patients with significant unmet medical needs may position the company favorably in the market.

Negative

• None.

SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2021 financial results after the U.S. financial markets close on Thursday, November 4, 2021. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.

The live webcast of the call will be available online at investor.oncternal.com and the call will be archived there for at least 30 days.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. More information is available at https://oncternal.com/.

Contact Information:

Investors
Richard Vincent
Chief Financial Officer
858-434-1113
rvincent@oncternal.com

Media
Corey Davis           
LifeSci Advisors
212-915-2577     
cdavis@lifesciadvisors.com

FAQ

What are Oncternal Therapeutics' upcoming financial results announcement details?

Oncternal Therapeutics will announce its third quarter 2021 financial results on November 4, 2021, after market close.

What time will Oncternal's management webcast be held?

The webcast will be held at 2:00 p.m. PT (5:00 p.m. ET) on November 4, 2021.

What does Oncternal Therapeutics focus on?

Oncternal focuses on developing novel oncology therapies for cancers with significant unmet medical needs.

What trials is Oncternal conducting with cirmtuzumab?

Cirmtuzumab is being evaluated in Phase 1/2 clinical trials for mantle cell lymphoma, chronic lymphocytic leukemia, and breast cancer.